Making bad cells go good: The promise of epigenetic therapy

Journal of Clinical Oncology

Volumn 23, Issue 17, 2005, Pages 3875-3876

  Sausville, Edward A ^a   Carducci, Michael A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5' AZACYTIDINE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; UNCLASSIFIED DRUG; VORINOSTAT; DNA (CYTOSINE 5) METHYLTRANSFERASE; ENZYME INHIBITOR;

B CELL LYMPHOMA; CANCER CELL; CANCER GENE THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CHROMATIN STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE REPLICATION; GENETIC TRANSCRIPTION; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SHORT SURVEY; ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; GENETIC EPIGENESIS; GENETICS; NEOPLASM; REVIEW;

ANIMALS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS;

EID: 21244437168     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.003     Document Type: Short Survey

References (14)

1. Leder A, Leder P: Butyric acid: A potent inducer of erythroid differentiation in cultured erythroleukemia cells. Cell 5:319-322, 1975
2. Cousens LS, Gallwitz D, Alberts BM: Different accessibilites in chromatin to histone acetylase. J Biol Chem 254:1716-1723, 1979
3. Feinberg AP: DNA methylation, genomic imprinting and cancer. Curr Top Microbiol Immunol 249:87-99, 2000
4. Rideout WM, Eversole-Cire P, Spruck CH, et al: Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation. Mol Cell Biol 14:6143-6152, 1994
5. Melnick AM, Adelson K, Licht JD: The theoretical basis of transcriptional therapy of cancer: Can it be put into practice? J Clin Oncol 23: 10.1200/JCO.2005.14.498
6. Bhalla KN: Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23: 10.1200/JCO.2005.16.600
7. Kelly WK, O'Connor OA, Krug LM, et al: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23: 10.1200/JCO.2005 .14.167
8. Ryan QC, Headlee D, Acharya M, et al: Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23: 10.1200/ JCO.2005.02.188
9. Samlowski WE, Leachman SA, Wade M, et al: Evaluation of a 7-day continuous intravenous infusion of decitabine: Inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 23: 10.1200/ JCO.2005.06.118
10. Rudek MA, Zhao M, He P, et al: Pharmacokinetics of 5-azacitidine given with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 23: 10.1200/JCO.2005 .07.450
11. Raval A, Lucas DM, Matkovic JJ, et al: TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol 23: 10.1200/ JCO.2005.02.196
12. Agrelo R, Setien F, Espada J, et al: Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma. J Clin Oncol 23: 10.1200/JCO.2005.11.650
13. Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J Clin Oncol 23: 10.1200/JCO.2005.02.998
14. van Doom R, Zoutman WH, Dijkman R, et al: Epigenetic profiling of cutaneous T-cell lymphoma: Promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 23: 10.1200/JCO.2005.11.353